Darkin S, Ralph R K
Cancer Lett. 1986 Jan;30(1):25-33. doi: 10.1016/0304-3835(86)90128-x.
Verapamil was shown to increase growth inhibition and decrease viability of PY815 mastocytoma cells treated with the anti-cancer drug mAMSA 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) or its normally inactive congener, 4'-(9-acridinylamino)methanesulphon-o-anisidide (oAMSA). Verapamil also potentiated the effect of sub-optimal concentrations of mAMSA or oAMSA on DNA scission in intact cells. Uptake of [14C]mAMSA by PY815 cells was considerably enhanced, while efflux of [14C]mAMSA from precharged cells was inhibited by verapamil. It is concluded that verapamil potentiates the action of mAMSA on PY815 cells in culture by reducing efflux of drug from the cells. The possibility that verapamil may affect systems that sequester or metabolize AMSA drugs is suggested.
维拉帕米被证明可增强抗癌药物4'-(9-吖啶基氨基)甲磺基间茴香胺(mAMSA)或其通常无活性的同系物4'-(9-吖啶基氨基)甲磺基邻茴香胺(oAMSA)处理的PY815肥大细胞瘤细胞的生长抑制作用并降低其活力。维拉帕米还增强了亚最佳浓度的mAMSA或oAMSA对完整细胞中DNA断裂的作用。维拉帕米显著增强了PY815细胞对[14C]mAMSA的摄取,同时抑制了预加载细胞中[14C]mAMSA的流出。结论是,维拉帕米通过减少药物从细胞中的流出增强了mAMSA对培养的PY815细胞的作用。提示维拉帕米可能影响螯合或代谢AMSA药物的系统。